CA3003943A1 - Method for vaccination against a self-antigen in a human patient - Google Patents
Method for vaccination against a self-antigen in a human patient Download PDFInfo
- Publication number
- CA3003943A1 CA3003943A1 CA3003943A CA3003943A CA3003943A1 CA 3003943 A1 CA3003943 A1 CA 3003943A1 CA 3003943 A CA3003943 A CA 3003943A CA 3003943 A CA3003943 A CA 3003943A CA 3003943 A1 CA3003943 A1 CA 3003943A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- self
- administration
- immune response
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15192794.4 | 2015-11-03 | ||
| EP15192794 | 2015-11-03 | ||
| PCT/EP2016/076372 WO2017076873A1 (en) | 2015-11-03 | 2016-11-02 | Method for vaccination against a self-antigen in a human patient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3003943A1 true CA3003943A1 (en) | 2017-05-11 |
Family
ID=54396782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3003943A Pending CA3003943A1 (en) | 2015-11-03 | 2016-11-02 | Method for vaccination against a self-antigen in a human patient |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12290553B2 (enExample) |
| EP (1) | EP3370761A1 (enExample) |
| JP (2) | JP7378931B2 (enExample) |
| KR (1) | KR102857456B1 (enExample) |
| CN (1) | CN108472344A (enExample) |
| AU (1) | AU2016348610B2 (enExample) |
| BR (1) | BR112018008697A2 (enExample) |
| CA (1) | CA3003943A1 (enExample) |
| RU (1) | RU2734924C2 (enExample) |
| WO (1) | WO2017076873A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102857456B1 (ko) * | 2015-11-03 | 2025-09-08 | 에이씨 이뮨 에스에이 | 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법 |
| AR111760A1 (es) * | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| CN112533959A (zh) * | 2018-05-22 | 2021-03-19 | 阿尔伯塔大学理事会 | 用于基于结构的淀粉样蛋白疾病疫苗和抗原的无害的、结构化的支架 |
| CA3185563A1 (en) | 2020-08-04 | 2022-02-10 | Dorian WINTER | Immunogenic compounds |
| KR102527616B1 (ko) | 2021-03-18 | 2023-05-02 | 정성욱 | 항체 관련 정보를 제공하는 방법 및 디바이스 |
| MX2024009485A (es) | 2022-02-09 | 2024-08-14 | Ac Immune Sa | Vacunas terapeuticas anti-alfa-sinucleina. |
| WO2025172592A1 (en) | 2024-02-15 | 2025-08-21 | Ac Immune Sa | Alpha synuclein therapeutic vaccine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077416A (zh) | 2002-10-23 | 2007-11-28 | 葛兰素史密丝克莱恩生物有限公司 | 抗疟疾的疫苗接种方法 |
| AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
| AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508569A1 (de) | 2009-07-23 | 2011-02-15 | Affiris Ag | Pharmaceutical compound |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
| US9408907B2 (en) | 2009-12-15 | 2016-08-09 | Glaxosmithkline Biologicals Sa | Homogenous suspension of immunopotentiating compounds and uses thereof |
| EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| DK3110439T3 (da) | 2014-02-28 | 2019-05-13 | Affiris Ag | Pcsk9-vacciner |
| KR102857456B1 (ko) | 2015-11-03 | 2025-09-08 | 에이씨 이뮨 에스에이 | 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법 |
-
2016
- 2016-11-02 KR KR1020187015512A patent/KR102857456B1/ko active Active
- 2016-11-02 CN CN201680064233.5A patent/CN108472344A/zh active Pending
- 2016-11-02 US US15/772,572 patent/US12290553B2/en active Active
- 2016-11-02 CA CA3003943A patent/CA3003943A1/en active Pending
- 2016-11-02 WO PCT/EP2016/076372 patent/WO2017076873A1/en not_active Ceased
- 2016-11-02 JP JP2018541534A patent/JP7378931B2/ja active Active
- 2016-11-02 AU AU2016348610A patent/AU2016348610B2/en active Active
- 2016-11-02 BR BR112018008697-5A patent/BR112018008697A2/en active Search and Examination
- 2016-11-02 RU RU2018120009A patent/RU2734924C2/ru active
- 2016-11-02 EP EP16793798.6A patent/EP3370761A1/en active Pending
-
2023
- 2023-08-24 JP JP2023136194A patent/JP7628333B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018008697A2 (en) | 2018-10-30 |
| US20190091306A1 (en) | 2019-03-28 |
| RU2734924C2 (ru) | 2020-10-26 |
| JP7628333B2 (ja) | 2025-02-10 |
| WO2017076873A1 (en) | 2017-05-11 |
| CN108472344A (zh) | 2018-08-31 |
| AU2016348610A1 (en) | 2018-05-10 |
| AU2016348610B2 (en) | 2023-08-31 |
| KR102857456B1 (ko) | 2025-09-08 |
| US12290553B2 (en) | 2025-05-06 |
| RU2018120009A3 (enExample) | 2020-04-23 |
| KR20180079406A (ko) | 2018-07-10 |
| RU2018120009A (ru) | 2019-12-04 |
| EP3370761A1 (en) | 2018-09-12 |
| JP7378931B2 (ja) | 2023-11-14 |
| JP2023175708A (ja) | 2023-12-12 |
| JP2018532782A (ja) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7628333B2 (ja) | ヒト患者における自己抗原に対するワクチン接種法 | |
| Wang et al. | UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease | |
| KR20110036809A (ko) | 파킨슨병과 관련된 증상을 치료하기 위한 화합물 | |
| JP5559789B2 (ja) | アルツハイマー病の処置のための免疫治療組成物 | |
| KR20120004994A (ko) | 치료적 이용 방법 | |
| US20150093431A1 (en) | Compositions | |
| US20160008443A1 (en) | METHOD FOR TREATING A beta-AMYLOIDOSIS | |
| JP2007522119A (ja) | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート | |
| Maier et al. | Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G) | |
| TW201345927A (zh) | 組成物 | |
| JP2023536497A (ja) | 免疫原性化合物 | |
| Ding et al. | Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice | |
| EA048154B1 (ru) | Иммуногенные соединения | |
| TW201348264A (zh) | 組成物 | |
| HUE025186T2 (en) | Methods and methods using supramolecular constructs | |
| NZ744411B2 (en) | Amyloid conjugate and uses and methods thereof | |
| NZ744411A (en) | Amyloid conjugate and uses and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211012 |
|
| EEER | Examination request |
Effective date: 20211012 |
|
| EEER | Examination request |
Effective date: 20211012 |
|
| EEER | Examination request |
Effective date: 20211012 |
|
| EEER | Examination request |
Effective date: 20211012 |
|
| EEER | Examination request |
Effective date: 20211012 |